Current Neuro-Oncology

Volume 27 Number 25
10 September 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 25, 10 September

Yan C, Bai X, Wu C, Ma W, Feng M.
Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma.
Front Oncol. 2025 Sep 2;15:1644934. doi: 10.3389/fonc.2025.1644934. PMID: 40963873. Observational study. ˍ

Nakai K, Kumada H, Matsumoto Y, Baba K, Murakami M, Ishida T, Saito T, Nakamura M, Numajiri H, Mizumoto M, Sugii N, Miki S, Ishikawa E, Maruo K, Takemura M, Hashimoto K, Takahashi T, Hayashi T, Sakurai H.
Boron neutron capture therapy (BNCT) phase I clinical trial for newly diagnosed glioblastoma by newly developed accelerator at University of Tsukuba.
Appl Radiat Isot. 2025 Sep 3;226:112152. doi: 10.1016/j.apradiso.2025.112152. PMID: 40945116.Interventional study protocol. ˍ

Timpanaro A, Song EZ, Toumi R, Elena-Sanchez L, Meechan M, Piccand C, Nemec K, Kordowski A, Lau D, Johnson S, Winter L, Rajendran A, Ronsley R, Oda SK, Gustafson J, Wendler JP, Koschmann C, Evans M, Pattwell S, Jensen MC, Foster JB, Dun MD, Biery MC, Vitanza NA.
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma.
bioRxiv [Preprint]. 2025 Sep 4:2025.09.01.673023. doi: 10.1101/2025.09.01.673023. PMID: 40950080. Lab investigation. ˍ

Barbato MI, Barone AK, Aungst SL, Miller CP, Ananthula S, Bi Y, Yang Y, Li X, Xiong Y, Fan J, Dorff SE, Zhao H, Zhou H, Pradhan S, Scepura B, Sinha AK, Stephenson M, Bhatnagar V, Saber H, Rahman NA, Tang S, Pazdur R, Kluetz PG, Larkins E, Drezner N. F
DA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery.
Clin Cancer Res. 2025 Sep 5:10.1158/1078-0432.CCR-25-1333. doi: 10.1158/1078-0432.CCR-25-1333. PMID: 40911439. Drug updates. ˍ

Wick W, Lanz LM, Wick A, Harting I, Dettmer S, Suwala AK, Ketter R, Tabatabai G, Seliger C, Glas M, Burger MC, Timmer M, Ringel FA, Mildenberger I, Schulz-Schaeffer WJ, Winkler F, König L, Herold-Mende C, Eisenmenger A, Pfister SM, Renovanz M, Bendszus M, Sahm F, Platten M, Kessler T.
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N²M² umbrella trial.
Nat Med. 2025 Sep 5. doi: 10.1038/s41591-025-03928-9. PMID: 40913172. Interventional study. ˍ

Hey GE, Still MEH, Moor RSF, Stanton A, Mitchell DA, Orr BA, Kresak JL, Yachnis AA, Massini T, Ghiaseddin AP.
A Rare Presentation of Adult Primary Leptomeningeal Medulloblastoma: Case Report.
Case Rep Pathol. 2025 Sep 8;2025:8937543. doi: 10.1155/crip/8937543. PMID: 40958970. Case report. ˍ

Cozzens JW, Drewes NB, Delfino KR, Chin KL, Amin DV, Lokaitis BC, Espinosa JA, Jones BA, Acakpo-Satchivi LJ, Dayoub H, Frankel MB, Agamah E, Rao K, Bradbury CM, Gao J.
Age is not a significant predictor of survival in patients with IDH-wildtype glioblastoma that undergo gross total resection and complete adjuvant chemoradiation.
Front Oncol. 2025 Sep 10;15:1657867. doi: 10.3389/fonc.2025.1657867. PMID: 41001028. Observational study. ˍ

Renovanz M, Hippler M, Kuchen R, Doerner L, Rieger D, Steinbach JP, Ronellenfitsch MW, Voss M, Kessler AF, Nickl V, Misch M, Onken JS, Rapp M, Nadji-Ohl M, Mehlitz M, Meixensberger J, Fehrenbach MK, Keric N, Ringel F, Coburger J, Lucas CW, Wehinger J, Schmidt-Graf F, Gempt J, Tatagiba M, Tabatabai G, Schranz M, Singer S.
Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).
J Neurooncol. 2025 Sep 10. doi: 10.1007/s11060-025-05223-6. PMID: 40931258. Interventional study. ˍ